FindTrial
Sign In

A medical records based study for selection of medicine depends on clinical characteristics between fluorouracil combined with oxaliplatin and irinotecan regimens and their effects on patients' life quality

A medical records based study for selection of medicine depends on clinical characteristics between fluorouracil combined with oxaliplatin and irinotecan regimens and their effects on patients' life quality

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029201
Enrollment
Unknown
Registered
2020-01-18
Start date
2020-02-01
Completion date
Unknown
Last updated
2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumour

Interventions

Group 1:mFOLFOX6
Group2:FOLFIRI

Sponsors

The First Affiliated Hospital of College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 98 Years

Inclusion criteria

Inclusion criteria: The patients with solid tumor who used mfolfox6 or FOLFIRI chemotherapy were searched through case system.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Heart, lung, kidney and other important organ failures; 3. Those who concurrently use irinotecan or oxaliplatin chemotherapy regimen; 4. Those who cannot perform tumor staging.

Design outcomes

Primary

MeasureTime frame
Quality of Life;—

Countries

China

Contacts

Public ContactZhao Qingwei

The First Affiliated Hospital of College of Medicine, Zhejiang University

qwzhao@zju.edu.cn+86 13588066886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026